Roth Capital Issues Pessimistic Estimate for TENX Earnings

Tenax Therapeutics, Inc. (NASDAQ:TENX) – Research analysts at Roth Capital decreased their Q1 2025 earnings per share (EPS) estimates for Tenax Therapeutics in a research report issued on Wednesday, March 26th. Roth Capital analyst J. Aschoff now forecasts that the specialty pharmaceutical company will post earnings per share of ($0.19) for the quarter, down from their previous forecast of ($0.18). The consensus estimate for Tenax Therapeutics’ current full-year earnings is ($0.88) per share. Roth Capital also issued estimates for Tenax Therapeutics’ Q2 2025 earnings at ($0.18) EPS, Q3 2025 earnings at ($0.19) EPS, Q4 2025 earnings at ($0.20) EPS, FY2025 earnings at ($0.76) EPS, FY2026 earnings at ($0.82) EPS, FY2027 earnings at ($0.79) EPS, FY2028 earnings at $1.99 EPS and FY2029 earnings at $3.27 EPS.

Several other analysts have also commented on the stock. William Blair restated an “outperform” rating on shares of Tenax Therapeutics in a report on Monday, March 10th. StockNews.com started coverage on Tenax Therapeutics in a research note on Friday, March 21st. They issued a “sell” rating on the stock. Finally, Leerink Partners set a $20.00 target price on shares of Tenax Therapeutics in a report on Monday, March 10th. One research analyst has rated the stock with a sell rating, three have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $18.00.

Tenax Therapeutics Stock Up 0.8 %

NASDAQ:TENX opened at $6.18 on Friday. Tenax Therapeutics has a twelve month low of $2.77 and a twelve month high of $7.89. The stock has a market cap of $24.50 million, a P/E ratio of -1.16 and a beta of 2.20. The firm’s fifty day simple moving average is $6.43 and its 200 day simple moving average is $5.40.

Tenax Therapeutics (NASDAQ:TENX) last posted its earnings results on Tuesday, March 25th. The specialty pharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.52) by $0.34.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Two Sigma Investments LP purchased a new stake in shares of Tenax Therapeutics in the fourth quarter worth $84,000. Sphera Funds Management LTD. bought a new position in Tenax Therapeutics in the 3rd quarter worth about $101,000. Geode Capital Management LLC lifted its stake in shares of Tenax Therapeutics by 32.4% in the fourth quarter. Geode Capital Management LLC now owns 24,354 shares of the specialty pharmaceutical company’s stock worth $151,000 after buying an additional 5,964 shares in the last quarter. Millennium Management LLC purchased a new stake in Tenax Therapeutics during the 4th quarter valued at $166,000. Finally, Vestal Point Capital LP purchased a new stake in Tenax Therapeutics during the 3rd quarter valued at $288,000. Hedge funds and other institutional investors own 1.67% of the company’s stock.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.